Literature DB >> 28164017

Alcohol septal ablation for hypertrophic obstructive cardiomyopathy in a patient with a chronic total occlusion of the right coronary artery: "beware of collateral damage".

Quentin de Hemptinne1, Fabien Picard1, Philippe L L'Allier1.   

Abstract

Alcohol septal ablation (ASA) is an effective semi-invasive alternative to surgical myectomy in selected patients for the management of severely symptomatic and drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). One contraindication of this procedure is the presence of collateral flow originating from the target septal perforator to a remote myocardial territory. In such circumstances, ethanol injection could cause remote non-target myocardial necrosis in the collateralized territory. Percutaneous revascularization of the collateralized vessel prior to ASA might cope with this contraindication by restoring normal antegrade flow in the occluded artery. We report a case that illustrates the feasibility and efficacy of such strategy.

Entities:  

Keywords:  Alcohol septal ablation (ASA); chronic total occlusion (CTO); collateral damage; hypertrophic obstructive cardiomyopathy (HOCM)

Year:  2017        PMID: 28164017      PMCID: PMC5253440          DOI: 10.21037/cdt.2016.08.01

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  13 in total

1.  Apical infarct via septal collateralization complicating transluminal alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  Walter A Parham; Morton J Kern
Journal:  Catheter Cardiovasc Interv       Date:  2003-10       Impact factor: 2.692

2.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.

Authors:  Shikhar Agarwal; E Murat Tuzcu; Milind Y Desai; Nicholas Smedira; Harry M Lever; Bruce W Lytle; Samir R Kapadia
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

3.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: collateral vessel communication between septal branches.

Authors:  Angelos Rigopoulos; Robert Sepp; Attila Palinkas; Imre Ungi; Dimitrios Th Kremastinos; Hubert Seggewiss
Journal:  Int J Cardiol       Date:  2006-07-14       Impact factor: 4.164

4.  Remote infarction following percutaneous transluminal septal myocardial ablation: a report of two cases.

Authors:  Nagamani Alur Chikkabasavaiah; Beeresha Puttegowda; Arunkumar Panneerselvam; Rajiv Ananthakrishna; Aravinda Prasad Kapanigowda; Ramesh Basavappa
Journal:  Cardiovasc Interv Ther       Date:  2010-11-05

5.  Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation.

Authors:  Michael A Fifer; Ulrich Sigwart
Journal:  Eur Heart J       Date:  2011-03-29       Impact factor: 29.983

6.  Early opening of dormant septal collaterals during alcohol septal ablation: a possible hazard of remote necrosis.

Authors:  Miloslav Spacek; David Zemanek; Pavol Tomasov; Josef Veselka
Journal:  Can J Cardiol       Date:  2013-09-20       Impact factor: 5.223

Review 7.  Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique.

Authors:  David R Holmes; Uma S Valeti; Rick A Nishimura
Journal:  Catheter Cardiovasc Interv       Date:  2005-11       Impact factor: 2.692

8.  Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries?

Authors:  Kerstin Wustmann; Stephan Zbinden; Stephan Windecker; Bernhard Meier; Christian Seiler
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

9.  Apical myocardial injury caused by collateralisation of a septal artery during ethanol septal ablation.

Authors:  S C Agarwal; I F Purcell; S S Furniss
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

Review 10.  A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.

Authors:  Max Liebregts; Pieter A Vriesendorp; Bakhtawar K Mahmoodi; Arend F L Schinkel; Michelle Michels; Jurriën M ten Berg
Journal:  JACC Heart Fail       Date:  2015-10-07       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.